Fierce Healthcare January 16, 2024
Demand remains high for GLP-1 drugs, and the experts at Morgan Health are aiming to support employers in managing that interest with a new report.
The organization, which is the healthcare-focused arm of banking giant JPMorgan Chase, hosted a panel at the J.P. Morgan Healthcare Conference last week on the topic, where it introduced several recommendations for firms to prepare for the ongoing interest in GLP-1s.
Morgan Health CEO Dan Mendelson told Fierce Healthcare that the challenge is to provide access to the drugs while ensuring that they’re part of an overall care management strategy for diabetes and obesity.
“This is amazing technology, and our employees want it,” he said. “And we want to make sure they have access to...
Today's Sponsors
Today's Sponsor